---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-035951"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:17:51.529816+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Seres sells VOWST business to Nestlé for up to $100M cash plus milestones; issues $15M stock

## Summary
- Cash payment of $100M at closing (net of ~$17.9M owed to Nestlé affiliate and ~CHF2M to Bacthera); $50M due Jan 2025, $25M July 2025.
- Prepaid $60M milestone for $150M annual net sales; future milestones of $125M at $400M and $150M at $750M in sales.
- Seres and Nestlé share 50/50 net profit/loss on VOWST in 2025 profit-sharing period.
- Nestlé to purchase 14,285,715 shares at $1.05/share ($15M); Seres to register resale within 90 days.
- Post-closing Seres to focus on SER-155 and other biotherapeutic candidates; stockholder vote required.

## SEC filing metadata
- accession: 0001140361-24-035951
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000114036124035951/0001140361-24-035951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000114036124035951/ny20030749x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-035951
- JSON: https://secwatch.observer/filing/0001140361-24-035951.json
- Plain text: https://secwatch.observer/filing/0001140361-24-035951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.